8-K: PDS Biotech Announces Q1 2025 Financial Results and Clinical Program Updates

PDS Biotechnology Corporation reported its Q1 2025 financial results, highlighted by the progress of the VERSATILE-003 Phase 3 clinical trial and upcoming presentations at ASCO.

Summary

• PDS Biotechnology Corporation announced its first quarter 2025 financial results and provided an update on its clinical programs.
• The company's VERSATILE-003 Phase 3 clinical trial evaluating Versamune HPV in recurrent/metastatic HPV16-positive head and neck squamous carcinoma (HNSCC) is underway, with site activation progressing and Mayo Clinic sites recently added.
• Three abstracts on Versamune HPV (PDS0101) were selected for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
• Preclinical data on a novel Infectimune-based universal flu vaccine were featured in presentations at the American Association of Immunologists IMMUNOLOGY2025 Annual Meeting.
• The FDA cleared an IND application for the combination of Versamune MUC1 and PDS01ADC to treat MUC1-positive unresectable, metastatic colorectal carcinoma.
• The company initiated its VERSATILE-003 Phase 3 trial in HPV16-positive first-line recurrent and/or metastatic HNSCC, designed to include approximately 350 patients.
• The company received FDA Fast Track designation for the combination of Versamune HPV and pembrolizumab in R/M HNSCC.
• PDS Biotech completed a registered direct offering, raising approximately $11 million initially, with a potential additional $11 million upon full warrant exercise.
• The net loss for Q1 2025 was approximately $8.5 million, or $0.21 per share, compared to $10.6 million, or $0.30 per share, for Q1 2024.
• Research and development expenses were $5.8 million for Q1 2025, compared to $6.7 million for Q1 2024.
• The company's cash balance as of March 31, 2025, was $40 million, compared to $41.7 million as of December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, FDA clearances, and a decrease in net loss compared to the previous year. However, the ongoing net loss and cash burn temper the overall sentiment.

Positives

• The VERSATILE-003 Phase 3 clinical trial is underway, indicating progress in the company's lead program.
• Multiple abstracts were selected for presentation at ASCO, increasing visibility and potential interest in Versamune HPV.
• FDA clearance of the IND application for Versamune MUC1 and PDS01ADC allows for clinical trials to proceed in colorectal cancer.
• FDA Fast Track designation for Versamune HPV and pembrolizumab could expedite the development and review process.
• The registered direct offering provided approximately $11 million in funding, with a potential additional $11 million upon full warrant exercise, strengthening the company's financial position.
• The net loss decreased from $10.6 million in Q1 2024 to $8.5 million in Q1 2025, indicating improved financial performance.
• Research and development expenses decreased from $6.7 million in Q1 2024 to $5.8 million in Q1 2025, suggesting improved efficiency.

Negatives

• The company reported a net loss of $8.5 million for Q1 2025, indicating ongoing losses.
• The company's cash balance decreased from $41.7 million as of December 31, 2024, to $40 million as of March 31, 2025, indicating cash burn.

Risks

• The company's dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates.
• The risks that raising such additional capital may restrict the company's operations or require the company to relinquish rights to the company's technologies or product candidates.
• The timing for the company or its partners to conduct clinical trials for Versamune HPV, PDS01ADC, Versamune MUC1 and other Versamune based product candidates.
• The future success of such trials.
• The successful implementation of the company's research and development programs and collaborations.
• The success, timing and cost of the company's ongoing clinical trials and anticipated clinical trials for the company's current product candidates.
• The company's ability to continue as a going concern.

Future Outlook

The company is focused on advancing its clinical programs, particularly the VERSATILE-003 Phase 3 trial, and presenting data at upcoming conferences. They anticipate continued progress in their research and development efforts.

Management Comments

• The first quarter of 2025 and recent weeks have been productive for PDS Biotech, highlighted by the initiation of our VERSATILE-003 Phase 3 clinical trial evaluating Versamune HPV in recurrent/metastatic (R/M) HPV16-positive head and neck squamous carcinoma (HNSCC), said Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech.
• We are pleased to announce that site activation is progressing, and that Mayo Clinic sites have recently been added to the trial.
• HPV16-positive HNSCC represents a large, rapidly growing patient population in need of targeted therapies to treat the underlying cause of the cancer, and our Versamune HPV investigational therapy is currently the only targeted therapy in a Phase 3 trial specifically for HPV-16 positive tumors.

Industry Context

PDS Biotech is operating in the competitive immunotherapy landscape, focusing on targeted therapies for cancers. The company's lead program, Versamune HPV, is being developed in combination with immune checkpoint inhibitors, reflecting a common strategy in the field. The focus on HPV16-positive HNSCC addresses a specific and growing patient population.

Comparison to Industry Standards

• The initiation of a Phase 3 trial for Versamune HPV in HPV16-positive HNSCC positions PDS Biotech alongside companies like Merck (Keytruda) and Bristol-Myers Squibb (Opdivo), which have established immune checkpoint inhibitors as standard-of-care treatments in various cancers.
• The development of a universal flu vaccine using the Infectimune platform places PDS Biotech in competition with companies like Moderna and Pfizer, which are also exploring mRNA-based flu vaccines.
• The collaboration with the National Cancer Institute (NCI) for the Phase 1/2 clinical trial of Versamune MUC1 + PDS01ADC is similar to other biotech companies partnering with government research institutions to accelerate drug development.

Stakeholder Impact

• Shareholders: The clinical progress and financial updates will likely influence investor sentiment and stock price.
• Patients: The development of new therapies for HPV16-positive HNSCC and colorectal cancer could provide new treatment options.
• Employees: The company's progress and financial stability impact job security and growth opportunities.
• Investors: The capital raise and clinical advancements will be of interest to current and potential investors.

Next Steps

• Continue site activation and patient enrollment for the VERSATILE-003 Phase 3 trial.
• Present abstracts on Versamune HPV at the 2025 ASCO Annual Meeting.
• Advance the Phase 1/2 clinical trial evaluating Versamune MUC1 + PDS01ADC in recurrent/metastatic colorectal cancer.
• Continue research and development efforts for the Infectimune-based universal flu vaccine.

Key Dates

Keywords

PDS Biotechnology, Versamune HPV, PDS0101, VERSATILE-003, HNSCC, Immunotherapy, Clinical Trial, Financial Results, ASCO, FDA, IND, PDS01ADC, Versamune MUC1, Infectimune, Universal Flu Vaccine